Northern Trust
CCCC icon

Northern Trust’s C4 Therapeutics CCCC Stock Holding History

Northern Trust’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$498K Buy
189,479
+23,272
+14% +$54.8K ﹤0.01% 3617
2025
Q4 		$317K Buy
166,207
+27,888
+20% +$66.1K ﹤0.01% 3811
2025
Q3 		$307K Sell
138,319
-1,354
-1% -$3.25K ﹤0.01% 3820
2025
Q2 		$200K Sell
139,673
-360,095
-72% -$524K ﹤0.01% 3938
2025
Q1 		$800K Buy
499,768
+4,725
+1% +$14.1K ﹤0.01% 3375
2024
Q4 		$1.78M Buy
495,043
+5,223
+1% +$26K ﹤0.01% 3091
2024
Q3 		$2.79M Buy
489,820
+310,247
+173% +$1.87M ﹤0.01% 2793
2024
Q2 		$830K Buy
179,573
+70,895
+65% +$423K ﹤0.01% 3325
2024
Q1 		$888K Buy
108,678
+1
+0% +$8 ﹤0.01% 3370
2023
Q4 		$614K Buy
108,677
+17,685
+19% +$40.3K ﹤0.01% 3473
2023
Q3 		$169K Sell
90,992
-166
-0.2% -$506 ﹤0.01% 3876
2023
Q2 		$251K Sell
91,158
-293,446
-76% -$943K ﹤0.01% 3737
2023
Q1 		$1.21M Sell
384,604
-14,428
-4% -$84.9K ﹤0.01% 3160
2022
Q4 		$2.35M Buy
399,032
+17,049
+4% +$141K ﹤0.01% 2913
2022
Q3 		$3.35M Buy
381,983
+11,463
+3% +$119K ﹤0.01% 2725
2022
Q2 		$2.79M Buy
370,520
+21,258
+6% +$187K ﹤0.01% 2865
2022
Q1 		$8.47M Sell
349,262
-12,434
-3% -$302K ﹤0.01% 2254
2021
Q4 		$11.6M Sell
361,696
-2,257
-0.6% -$89.3K ﹤0.01% 2129
2021
Q3 		$16.3M Buy
363,953
+60,574
+20% +$2.59M ﹤0.01% 1938
2021
Q2 		$11.5M Buy
303,379
+184,303
+155% +$6.6M ﹤0.01% 2272
2021
Q1 		$4.41M Sell
119,076
-5,994
-5% -$238K ﹤0.01% 2834
2020
Q4 		$4.14M Buy
+125,070
New +$3.63M ﹤0.01% 2786

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust's CCCC Position: Q1 2026 in Review

Northern Trust increased its C4 Therapeutics (CCCC) stake by 14% in Q1 2026, buying an estimated $54.8K and bringing the position to 189,479 shares worth $498K. The position accounts for ﹤0.01% of the portfolio, ranked #3617.

Northern Trust first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $16.3M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Northern Trust held 189,479 shares of C4 Therapeutics worth $498K as of Q1 2026.
  • Northern Trust bought 23,272 C4 Therapeutics shares in Q1 2026, an estimated $54.8K.
  • C4 Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3617 holding.
  • Northern Trust first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Northern Trust's C4 Therapeutics position peaked at $16.3M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.